Which of the following is the most appropriate drug used for chelation therapy in beta thalassemia major?
**Core Concept**
The management of beta thalassemia major involves iron overload due to frequent blood transfusions, necessitating chelation therapy to reduce iron levels. This question assesses the student's knowledge of chelation therapy agents used in this condition.
**Why the Correct Answer is Right**
Deferoxamine (D) is an iron-chelating agent that binds to free iron in the body, making it suitable for chelation therapy in beta thalassemia major. It is administered via subcutaneous infusion over 8-12 hours, and its efficacy is well-established in reducing iron levels and preventing complications associated with iron overload.
**Why Each Wrong Option is Incorrect**
**Option A:** Desferoxamine is not administered orally, making it less suitable for patients who require long-term therapy. Its subcutaneous route may lead to discomfort and adherence issues.
**Option B:** Succimer is a chelating agent used primarily for lead poisoning, not iron overload in beta thalassemia major.
**Option C:** Penicillamine is used in the treatment of Wilson's disease and other heavy metal poisonings but is not the preferred agent for iron chelation in beta thalassemia major.
**Clinical Pearl / High-Yield Fact**
Deferiprone (Ferriprox) is another oral iron chelator used in the management of iron overload in beta thalassemia major, offering an alternative to deferoxamine for patients who require long-term therapy.
**Correct Answer:** D. Deferoxamine.